Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 3/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | PARL | Q9H300 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7325260 | 0.78 | HPGD (0.46) | PTGS1ALDH1A1PTGS2TLR2TLR1 | |
| SCHEMBL1260380 | 0.78 | TLR2 (0.65) | PTGS1ALDH1A1PTGS2TLR2TLR1 | |
| SCHEMBL11901049 | 0.78 | TLR2 (0.48) | ALDH1A1PTGS2TLR2TLR1MEN1 | |
| SCHEMBL5606561 | 0.77 | PTGS2 (0.52) | PTGS1PTGS2 | |
| SCHEMBL23884749 | 0.76 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL22465893 | 0.76 | HTR2A (0.42) | ALDH1A1TLR2TLR1POLBHTR2A | |
| SCHEMBL1037500 | 0.76 | HTT (0.51) | ALDH1A1TLR2TLR1POLBHTR2A | |
| SCHEMBL11899949 | 0.76 | NR2E1 (0.42) | PTGS1PTGS2MAPT | |
| SCHEMBL8819363 | 0.76 | PTGS2 (0.40) | PTGS1PTGS2 | |
| SCHEMBL31314846 | 0.76 | NPC1 (0.50) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2673260-B1 | GLUCAGON RECEPTOR MODULATOR | PFIZER (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2673260-B1 | GLUCAGON RECEPTOR MODULATOR | PFIZER (US) | 2016-08-17 | — | — | EP | disclosed |
| CN-103370306-B | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-12-02 | — | — | CN | disclosed |
| US-20150266859-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266859-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9073871-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-07-07 | — | — | US | disclosed |
| CN-104744370-A | Glucagon receptor modulators | PFIZER | 2015-07-01 | — | — | CN | disclosed |
| US-20140371467-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8859591-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130296355-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER (US) | 2013-11-07 | — | — | US | disclosed |
| CN-103370306-A | Glucagon receptor modulators | PFIZER | 2013-10-23 | — | — | CN | disclosed |
| US-8507533-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507533-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266859-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | PTGS1 706/4885ALDH1A1 2684/4885PTGS2 1361/4885 |
| US-20130296355-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | PTGS1 706/4885ALDH1A1 2684/4885PTGS2 1361/4885 |
| US-20140371467-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | PTGS1 706/4885ALDH1A1 2684/4885PTGS2 1361/4885 |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | PTGS1 706/4885ALDH1A1 2684/4885PTGS2 1361/4885 |
| US-20120202834-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | PTGS1 706/4885ALDH1A1 2684/4885PTGS2 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.